BMS-986118, with the CAS number 1610562-74-7, is a chemical compound developed by Bristol-Myers Squibb, primarily investigated for its potential therapeutic applications in the treatment of various diseases, including autoimmune disorders and certain cancers. It functions as a selective inhibitor of specific enzymes or pathways involved in disease progression, showcasing a targeted mechanism of action. The compound is characterized by its unique molecular structure, which contributes to its biological activity and pharmacokinetic properties. BMS-986118 is typically evaluated for its efficacy, safety, and tolerability through preclinical and clinical trials. As with many investigational drugs, its development involves rigorous testing to determine optimal dosing, potential side effects, and interactions with other medications. The ongoing research aims to elucidate its full therapeutic potential and establish its role in clinical practice. As of the latest updates, detailed information regarding its specific characteristics, such as solubility, stability, and metabolic profile, may still be under investigation or proprietary to the developing entity.

BMS-986118 is a  GPR40 full agonist.  GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been_x000D_
a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secretion only in the presence of elevated blood glucose levels, minimizing the risk of hypoglycemia.

BMS-986118

1610562-74-7: BMS-986118, with the CAS number 1610562-74-7, is a chemical compound developed by Bristol-Myers Squibb, primarily investigated for its potential therapeutic applications in the treatment of various diseases, including autoimmune disorders and certain cancers. It functions as a selective inhibitor of specific enzymes or pathways involved in disease progression, showcasing a targeted mechanism of action. The compound is characterized by its unique molecular structure, which contributes to its biological activity and pharmacokinetic properties. BMS-986118 is typically evaluated for its efficacy, safety, and tolerability through preclinical and clinical trials. As with many investigational drugs, its development involves rigorous testing to determine optimal dosing, potential side effects, and interactions with other medications. The ongoing research aims to elucidate its full therapeutic potential and establish its role in clinical practice. As of the latest updates, detailed information regarding its specific characteristics, such as solubility, stability, and metabolic profile, may still be under investigation or proprietary to the developing entity.

<p>BMS-986118 is a GPR40 full agonist targeting type II diabetes, prompting insulin release without hypoglycemia risk.</p>

CAS 1610562-74-7

BMS-986118

BMS-986118

Ref: TM-T26868